Immunotherapy in Patients With Dementia or Cognitive Impairment — Consent, Reporting and the Decision

Sometimes, yes. Dementia is not by itself a bar to immunotherapy. What decides it is the stage of the dementia, the person’s general fitness, whether the cancer needs this treatment at all, whether consent can be taken properly, and whether someone at home can reliably notice and report side effects.

That last item is the one families are rarely told about, and it does the most work. Immunotherapy is not difficult because it is strong. It is manageable because immune-related side effects are usually caught early — and they are caught early because a patient says “my stomach has been loose for three days” or “I get breathless walking to the toilet now”. Detecting an immune-related side effect depends on symptom reporting. In dementia, that dependency is the whole problem.

So the real question is not “is she too confused for treatment”. It is “if something changes in her body, will anyone know in time” — and that is a question about the household as much as about the patient. It is answerable. It is worth answering before anyone signs anything.

Nothing on this page can tell you whether your relative is eligible. That assessment belongs to a medical oncologist working with the doctors who manage their memory and their other conditions, with the case discussed at a multidisciplinary tumour board. What follows is what that assessment actually looks at.

Often, yes. Capacity is judged for one decision at a time, not granted or removed for life. Someone may be unable to manage money and still understand that a drip may help their cancer and may make them unwell. Where capacity for this decision is missing, the family decides with the treating team, in the patient’s best interests.

Capacity also moves. It is usually better in the morning, worse when the person is tired, in pain, constipated, dehydrated, running an infection or sitting in an unfamiliar room. A consultation squeezed into a noisy afternoon clinic will find less capacity than the same conversation held at nine in the morning, in the person’s own language, with the hearing aid in. That is not a technicality. It changes who gets to decide.

What is being tested is narrow and practical: can they take in the information, hold it long enough to weigh it, and say what they want? Explained plainly — “a drip, once every few weeks, that may shrink the cancer and may upset your stomach or make you very tired” — more people manage this than the label “dementia” suggests. Ask for it to be attempted properly, and more than once, before it is written off.

Where capacity genuinely is not there, India’s legal position is worth knowing honestly. There is no single statute here equivalent to a mental-capacity act governing medical decisions for adults who can no longer decide for themselves. In practice consent is taken from the next of kin and recorded in the notes — who was present, what was explained, what the patient themselves indicated. The Rights of Persons with Disabilities Act, 2016 provides for limited guardianship through a designated authority where a formal arrangement is needed; that is a legal step taken outside the hospital, not something an oncology team can arrange for you.

Two things are worth doing early. First, write down anything the person said or wrote about treatment while they could still express a view — the Supreme Court recognised advance medical directives in India in 2018 and simplified the procedure in 2023, and although those rules are written around end-of-life decisions rather than routine consent, a recorded wish carries real weight in the discussion. Second, settle within the family who is speaking for the patient. Disagreement discovered halfway through a treatment course is far harder than disagreement settled before it starts.

Assent matters even where formal capacity does not. If someone pulls the cannula out every visit, refuses to sit for the infusion, or is frightened each time, that is information and it belongs in the review. Treatment that would need restraint is not treatment anyone should be planning.

There is one trap here that catches almost every family, and it is worth naming before the table. When someone with dementia goes downhill, the explanation reached for first is the dementia. On immunotherapy that assumption is unsafe. A new change is treated as a treatment side effect until a doctor has said otherwise — not the other way round.

General patient-education guidance only, not a home-management plan. If any of the above appears, the decision about what it is belongs to a doctor, not to the family. If you cannot reach the treating team, call 1800 202 8726, and go to the nearest emergency department if the person is breathless, in chest pain, bleeding, collapsing or much more confused than usual.

Blood tests before every cycle carry part of this load. Thyroid, liver and kidney changes usually show in the bloods before anyone feels anything, which is a genuine safety net for a patient who cannot describe symptoms. It is a net with wide holes: bowel, lung and heart inflammation are found by someone noticing, not by a routine test. That is why the observer is part of the treatment plan, not an optional extra.

Here is the framework, in the order it runs. It is a framework, not a recommendation — no page can tell you what the answer should be for your relative, and anyone who offers you that answer without seeing the reports is guessing.

• One named observer — one person who knows the normal day, rather than five people each seeing an hour of it.
• A half-line written every day — toilet, food, breathing, mood, skin. Two weeks of that beats anyone’s memory of “she seemed off”.
• The full medicine list — prescriptions, over-the-counter tablets, supplements, and any herbal or traditional preparation, asked about without judgement.
• One phone number on the fridge — the oncology day-care number, with the treatment card kept beside it.
• A plan for a bad night — who drives, which hospital, decided in advance. “Go now” has to be possible at 2am.
• A note of what they wanted — anything said or written about treatment while they could, and who they trusted to decide.

If you read that list and think no one in the household can hold it, say so in the consultation. It is not a failure and it is not a reason to be judged. It is a clinical fact that changes the plan, and it is far better said in a clinic room than discovered in an emergency department.

• If depression, anxiety, bipolar disorder or schizophrenia is also in the picture, Immunotherapy and Existing Mental Health Conditions covers how that changes consent, monitoring and medicine review.
• If the diagnosis is an unusual one and no standard protocol seems to exist, Immunotherapy for Rare Cancers With No Standard Treatment explains how those decisions are reached.
• If your relative has had a previous cancer as well as this one, Immunotherapy for Patients With a Second Cancer deals with the sequencing question.
• For how the treatment itself is given, monitored and followed up as day care, see Immunotherapy at CION Cancer Clinics.

General patient-education information only. Nothing here states or implies that immunotherapy is suitable, safe or unsuitable for your relative — that assessment is made by the treating medical oncologist together with the doctors who manage their memory and their other conditions, and is discussed at a multidisciplinary tumour board. Immunotherapy is administered as day care at CION centres; response-assessment PET-CT is coordinated at partner imaging centres. The legal points on this page describe the general position in India and are not legal advice.

Bring the Question to a Tumour Board, Not a Corridor

Bring the reports, the full medicine list and an honest account of a normal day at home. Free, and with no commitment to start treatment.

This page is general patient-education information, not a substitute for the assessment your own oncology, geriatric and memory-care teams make for your relative’s specific case.